Abbott Laboratories

Amgen Inc

Gilead Sciences Inc

Eli Lilly & Co.

Novo-Nordisk A/S

SANOFI ORD

In the latest episode of 'In Good Company', Nicolai Tangen speaks to the CEO of Novo Nordisk $NVO, Lars Fruergaard Jørgensen. They discuss various topics around:

- How obesity impacts people's life
- Lars's concerns about lack of access for most people to some of the new medicines
- The importance of purpose and Novo Nordisk $NVO new weight loss drug

$ABT $AMGN $GILD $LLY $SNYNF

Tagging @ifb_podcast who might be interested into the conversation, in particular.

![Image upload](https://cdn.commonstock.com/efdf7a27af9ad3420b7c54f7d56bde2ef9de8b119cd611e944ab7161b73776db-560x300.jpg)
_Source: FirstWord Pharma_

[https://podcasts.apple.com/no/podcast/lars-fruergaard-j%C3%B8rgensen-ceo-of-novo-nordisk/id1614211565?i=1000604237480](https://podcasts.apple.com/no/podcast/lars-fruergaard-j%C3%B8rgensen-ceo-of-novo-nordisk/id1614211565?i=1000604237480)

Oh I am 👏👏. Thanks for tagging me 😁

Dave Ahern

Podcast Episode · In Good Company with Nicolai Tangen · 15/03/2023 · 38m

https://podcasts.apple.com/no/podcast/lars-fruergaard-j%C3%B8rgensen-ceo-of-novo-nordisk/id1614211565?i=1000604237480

Lars Fruergaard Jørgensen CEO of Novo Nordisk

Lars Fruergaard Jørgensen CEO of Novo Nordisk $NVO ('In Good Company' - Nicolai Tangen)

This member is verified by the Commonstock team based on their contributions to the Commonstock community. 